Overview

A Study to Assess the Pharmacokinetics, Safety, and Efficacy of Two Doses of Bimekizumab in Adolescent Study Participants With Moderate to Severe Plaque Psoriasis

Status:
Recruiting
Trial end date:
2025-03-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to assess th pharmacokinetics (PK) of bimekizumab administered subcutaneously (sc) in adolescents with moderate to severe plaque psoriasis (PSO).
Phase:
Phase 2
Details
Lead Sponsor:
UCB Biopharma SRL